ホーム › 子宮内膜がん › イリノイ州 › Chicago
Chicago、ILにおける子宮内膜がんの臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、子宮内膜がんに関する25件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- 他3件
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
被験者募集中第1相
- University of Chicago Comprehensive Cancer Center, Chicago
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
被験者募集中第3相
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- University of Illinois Cancer Center, Chicago
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
被験者募集中観察研究
- University of Chicago, Chicago
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Chicago
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
被験者募集中第1/2相
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago Medical Center, Chicago
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
被験者募集中第2相
- Northwestern University, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Northwestern University Feinberg School of Medicine, Chicago
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
被験者募集中第3相
- University of Chicago Medical Center ( Site 5002), Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
被験者募集中第1相
- University of Chicago Medical Center, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Lurie Children's Hospital-Chicago, Chicago
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
被験者募集中第2相
- Northwestern Medicine, Chicago
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
被験者募集中第1/2相
- University of Chicago Medical Center, Chicago
A Study of PHST001 in Advanced Solid Tumors
被験者募集中第1相
- University of Chicago Medical Center, Chicago
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
被験者募集中第3相
- Research Site, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Northwestern University, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
被験者募集中第1相
- The University of Chicago Medical Center (UCMC), Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
被験者募集中第1/2相
- Northwestern Memorial Hospital, Chicago
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
被験者募集中
- Northwestern University, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- University of Chicago Medical Center, Chicago
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
被験者募集中
- Northwestern Memorial Hospital, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
被験者募集中観察研究健康なボランティア歓迎
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
他の都市における子宮内膜がんの試験
- Houston, TX68件の研究
- New York City, NY52件の研究
- Boston, MA50件の研究
- Arlington, VA39件の研究
- Nashville, TN38件の研究
- Los Angeles, CA34件の研究
- St. Louis, MO29件の研究
- Philadelphia, PA28件の研究
- San Antonio, TX27件の研究
- Columbus, OH25件の研究
- Queens, NY25件の研究
- Oklahoma City, OK25件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん58件の研究
- がん（全種類）51件の研究
- 転移性癌45件の研究
- 前立腺がん45件の研究
- 肥満症41件の研究
- 肺がん41件の研究
- 卵巣がん36件の研究
- 脳卒中34件の研究
- 大腸癌33件の研究
- 心不全31件の研究
- 過体重28件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。